NCT05247489

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 55 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 12 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Conditions

• Vitiligo

Interventions

Type	Name	Description
DRUG	Ruxolitinib 1.5% cream	Ruxolitinib cream 1.5% applied twice a day (BID).
DEVICE	NB-UVB phototherapy	NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit

Timeline

• Start date: 2022-05-05
• Primary completion: 2023-12-19
• Completion: 2023-12-19
• First posted: 2022-02-21
• Last updated: 2025-02-20
• Results posted: 2025-02-20

Locations

13 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study